Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T Lymphoblastic Leukemia and T Lymphoblastic Lymphoma
Latest Information Update: 27 Nov 2022
At a glance
- Drugs SenL-T7 (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hebei Senlang Biotechnology
Most Recent Events
- 24 Nov 2022 New trial record